Abstract
The effect of oral administration of a new beta blocker trimepranol (1‐[3,5,6‐trimethyl‐4‐acetoxyphenoxyl‐3‐isopropylamino‐2‐propanol]) on serum levels of growth hormone (GH), immunoreactive insulin (IRI), glucose, and free fatty acids (FFA) has been studied in normal persons. Fasting levels of GH, IRI, glucose, and FFA after trimepranol were not changed. The concentration of glucose and secretory response of IRI during oral glucose tolerance test decreased after trimepranol. The insulinogenic index was not changed. The total secretory response of GH during glucose tolerance test after trimepranol was enhanced. The levels of FFA during glucose tolerance test were not changed.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
